Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | BDKRB2 | P30411 | 4/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24338625 | 0.88 | GRIN2B (0.38) | TSHRGRIN2BGRIN2CBDKRB2DPP4 | |
| SCHEMBL26378804 | 0.88 | GRIN2B (0.38) | TSHRGRIN2BGRIN2CBDKRB2DPP4 | |
| SCHEMBL19852817 | 0.85 | TSHR (0.41) | TSHRGRIN2BGRIN2CBDKRB2APEX1 | |
| SCHEMBL19852896 | 0.85 | TSHR (0.36) | TSHRGRIN2BGRIN2CBDKRB2 | |
| SCHEMBL19852893 | 0.84 | TSHR (0.35) | TSHRGRIN2BGRIN2CBDKRB2 | |
| SCHEMBL24620374 | 0.84 | GRIN2B (0.36) | TSHRGRIN2BGRIN2CBDKRB2ENPP2 | |
| SCHEMBL24620375 | 0.83 | DPP4 (0.37) | TSHRGRIN2BGRIN2CBDKRB2DPP4 | |
| SCHEMBL19852941 | 0.83 | TSHR (0.35) | TSHRBDKRB2ENPP2APEX1BLM | |
| SCHEMBL19852949 | 0.81 | TSHR (0.40) | TSHRGRIN2BGRIN2CBDKRB2ENPP2 | |
| SCHEMBL24338601 | 0.79 | TSHR (0.38) | TSHRBDKRB2ENPP2APEX1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312591-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2023-10-05 | — | — | US | disclosed |
| US-20230312591-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2023-10-05 | — | — | US | disclosed |
| US-11530223-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220220119-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-07-14 | — | — | US | disclosed |
| US-11299495-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2022-04-12 | — | — | US | disclosed |
| WO-2018026779-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299495-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | TSHR 1842/4885GRIN2B 5/4885GRIN2C 4/4885 |
| US-11530223-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | TSHR 1842/4885GRIN2B 5/4885GRIN2C 4/4885 |
| US-20220220119-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | TSHR 1842/4885GRIN2B 5/4885GRIN2C 4/4885 |
| US-20230312591-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | TSHR 1842/4885GRIN2B 5/4885GRIN2C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.